These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26199720)

  • 21. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication.
    da Silva Alves F; Figee M; van Amelsvoort T; Veltman D; de Haan L
    Psychopharmacol Bull; 2008; 41(1):121-32. PubMed ID: 18362875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of schizophrenia and comorbid substance use disorder.
    Green AI; Salomon MS; Brenner MJ; Rawlins K
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):129-39. PubMed ID: 12769622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Illness appraisals and self-esteem as correlates of anxiety and affective comorbid disorders in schizophrenia.
    Karatzias T; Gumley A; Power K; O'Grady M
    Compr Psychiatry; 2007; 48(4):371-5. PubMed ID: 17560959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subjective well-being of patients with schizophrenia as a target of drug treatment.
    Karamatskos E; Mulert C; Lambert M; Naber D
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1490-9. PubMed ID: 22283757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study.
    Lomeña F; Catafau AM; Parellada E; Bernardo M; Font M; Gutiérrez F; Pavía J
    Psychopharmacology (Berl); 2004 Mar; 172(2):165-9. PubMed ID: 14624330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schizophrenia: from developmental deviance to dopamine dysregulation.
    Murray RM; Lappin J; Di Forti M
    Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S129-34. PubMed ID: 18499406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.
    Eisenberg DP; Yankowitz L; Ianni AM; Rubinstein DY; Kohn PD; Hegarty CE; Gregory MD; Apud JA; Berman KF
    Neuropsychopharmacology; 2017 Oct; 42(11):2232-2241. PubMed ID: 28387222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cannabis and schizophrenia: demographic and clinical correlates].
    Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
    Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.
    Veselinović T; Scharpenberg M; Heinze M; Cordes J; Mühlbauer B; Juckel G; Rüther E; Paulzen M; Haen E; Hiemke C; Timm J; Gründer G;
    J Clin Psychopharmacol; 2019; 39(6):550-560. PubMed ID: 31688449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Epidemiology, etiology and treatment of patients with psychosis and co-morbid substance use disorder].
    Moggi F
    Ther Umsch; 2018 Jun; 75(1):37-43. PubMed ID: 29909760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y
    Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.
    Petrakis IL; O'Malley S; Rounsaville B; Poling J; McHugh-Strong C; Krystal JH;
    Psychopharmacology (Berl); 2004 Mar; 172(3):291-7. PubMed ID: 14634716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The dopamine hypothesis of schizophrenia. New findings for an old theory].
    Heinz A
    Nervenarzt; 2000 Jan; 71(1):54-7. PubMed ID: 10695033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse.
    Voruganti LN; Heslegrave RJ; Awad AG
    J Nerv Ment Dis; 1997 Jul; 185(7):463-5. PubMed ID: 9240366
    [No Abstract]   [Full Text] [Related]  

  • 37. Dopamine in schizophrenia.
    Hietala J; Syvälahti E
    Ann Med; 1996 Dec; 28(6):557-61. PubMed ID: 9017115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Adolescence, schizophrenia and drug abuse: interactive vulnerability. A hypothesis].
    van Nimwegen L; de Haan L; van Beveren N; van den Brink W; Linszen D
    Tijdschr Psychiatr; 2007; 49(3):169-78. PubMed ID: 17370223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical comorbidity in schizophrenia.
    Jeste DV; Gladsjo JA; Lindamer LA; Lacro JP
    Schizophr Bull; 1996; 22(3):413-30. PubMed ID: 8873293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.
    Caravaggio F; Hahn M; Nakajima S; Gerretsen P; Remington G; Graff-Guerrero A
    Med Hypotheses; 2015 Oct; 85(4):391-6. PubMed ID: 26118462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.